L
Lan Zhao
Researcher at Imperial College London
Publications - 76
Citations - 2950
Lan Zhao is an academic researcher from Imperial College London. The author has contributed to research in topics: Pulmonary hypertension & Hypoxia (medical). The author has an hindex of 31, co-authored 68 publications receiving 2497 citations. Previous affiliations of Lan Zhao include University of Giessen & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Histone Deacetylation Inhibition in Pulmonary Hypertension Therapeutic Potential of Valproic Acid and Suberoylanilide Hydroxamic Acid
Lan Zhao,Chien-Nien Chen,Nabil Hajji,Eduardo Oliver,Emanuele Cotroneo,John Wharton,Daren Wang,Min Li,Timothy A. McKinsey,Kurt R. Stenmark,Martin R. Wilkins +10 more
TL;DR: In this paper, the contribution of histone deacetylase (HDAC) activity to the development of pulmonary arterial hypertension, a condition characterized by profound structural remodeling of pulmonary arteries and arterioles, was investigated.
Journal ArticleDOI
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients
Evangelos D. Michelakis,Vikram Gurtu,Linda Webster,Gareth Barnes,Geoffrey Watson,Luke Howard,John Cupitt,Ian Paterson,Richard B. Thompson,Kelvin Chow,Declan P. O'Regan,Lan Zhao,John Wharton,David G. Kiely,Adam Kinnaird,Aristeidis E. Boukouris,Christopher W. White,Jayan Nagendran,Darren H. Freed,Stephen J. Wort,J. Simon R. Gibbs,Martin R. Wilkins +21 more
TL;DR: This first-in-human trial of a mitochondria-targeting drug in iPAH demonstrates that PDK is a druggable target and offers hemodynamic improvement in genetically susceptible patients, paving the way for novel precision medicine approaches in this disease.
Journal ArticleDOI
Pivotal Role for Endothelial Tetrahydrobiopterin in Pulmonary Hypertension
Jeffrey Khoo,Lan Zhao,Nicholas J. Alp,Jennifer K. Bendall,Taija Nicoli,K A Rockett,Martin R. Wilkins,Keith M. Channon +7 more
TL;DR: Endothelial BH4 availability is essential for maintaining pulmonary vascular homeostasis, is a critical mediator in the pathogenesis of pulmonary hypertension, and is a novel therapeutic target.
Journal ArticleDOI
Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension
Peter M. George,Eduardo Oliver,Peter Dorfmüller,Olivier Dubois,Daniel M. Reed,Nicholas S. Kirkby,Nura A. Mohamed,Frédéric Perros,Fabrice Antigny,Elie Fadel,Benjamin E. Schreiber,Alan M. Holmes,Mark Southwood,Guy Hagan,Stephen J. Wort,Nathan W. Bartlett,Nicholas W. Morrell,John G Coghlan,Marc Humbert,Lan Zhao,Jane A. Mitchell +20 more
TL;DR: Data indicate that type I IFN, via an action of IFNAR1, mediates PAH, a link between interferon (IFN) and pulmonary arterial hypertension (PAH).
Journal ArticleDOI
Beneficial Effects of Phosphodiesterase 5 Inhibition in Pulmonary Hypertension Are Influenced by Natriuretic Peptide Activity
TL;DR: The natriuretic peptide pathway influences the response to PDE5 inhibition in hypoxia-induced pulmonary hypertension, particularly its effects on RV hypertrophy and vascular remodeling.